An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Quantum-Si Joins Human Proteome Organization (HUPO) Industrial Advisory Board
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Quantum-Si, known as The Protein Sequencing Company™, has joined the Human Proteome Organization (HUPO) Industrial Advisory Board. This collaboration aims to advance proteomics technologies and enhance understanding of human diseases. Dan Hanson and Dr. Brian Reed will represent Quantum-Si, which is actively participating in HUPO's 21st World Congress in Cancun and the upcoming US HUPO Conference in Chicago. CEO Jeff Hawkins emphasized the importance of protein sequencing in revolutionizing life science research and drug discovery.
Positive
Joining HUPO's Industrial Advisory Board may strengthen Quantum-Si's influence in proteomics.
Participation in international conferences can enhance visibility and networking opportunities.
Negative
Leadership transition raises concerns about continuity and experience.
The Protein Sequencing Company™ Commercializing the Industry’s First System to Enable Next-Generation, Single-Molecule Protein Sequencing Will Serve on HUPO’s Industrial Advisory Board
GUILFORD, Conn.--(BUSINESS WIRE)--
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced it has joined the Human Proteome Organization (HUPO) Industrial Advisory Board (IAB), an international scientific organization focused on fostering collaboration and promoting new technologies in the proteomics sphere. Dan Hanson, Director of Product, and Dr. Brian Reed, Head of Research, will represent Quantum-Si and support HUPO’s mission to advance proteomics technologies, techniques and training to better understand human disease.
“Protein sequencing represents the new frontier in the field of proteomics which will further unfold our understanding of disease, impact all aspects of life science research, and like next-generation DNA sequencing before it, provide a much richer, much deeper picture of our health and biology,” said Jeff Hawkins, Chief Executive Office of Quantum-Si. “Quantum-Si is committed to HUPO’s mission of fostering global collaboration to advance major proteomics projects, technologies, and techniques, as well as helping guide the industry through its current, explosive growth.”
Quantum-Si is participating in the 21stHUPO World Congress, which is currently taking place in Cancun, Mexico, on December 4-8, 2022. In addition, the Company is looking forward to participating in the 19th Annual US HUPO Conference, taking place in Chicago, IL on March 4-8, 2023.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.
About HUPO
Founded in 2001, the Human Proteome Organization (HUPO) is a 501(c)(3) tax exempt non-profit organization registered in the state of New Mexico. HUPO is an international scientific organization representing and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques and training.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; our ongoing leadership transition; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the potential attributes and benefits of the Company's products and services; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that the Company is developing; the size and growth potential of the markets for the Company's future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services following anticipated commercial launch; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company’s Annual Report for the fiscal year ended December 31, 2021, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
What is the significance of Quantum-Si joining the HUPO Industrial Advisory Board?
Quantum-Si's participation in the HUPO Industrial Advisory Board is intended to foster collaboration and advance proteomics technologies, enhancing its role in the industry.
Who will represent Quantum-Si on the HUPO board?
Dan Hanson, Director of Product, and Dr. Brian Reed, Head of Research, will represent Quantum-Si on the HUPO board.
When is Quantum-Si participating in the HUPO World Congress?
Quantum-Si is participating in the 21st HUPO World Congress from December 4-8, 2022, in Cancun, Mexico.
What are the potential impacts of Quantum-Si's participation in HUPO?
Quantum-Si's involvement in HUPO could lead to advancements in proteomics technologies and collaborations that may benefit its business operations and product development.
